A Randomized, Partially Masked, Controlled, Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD (ATMOSPHERE)
Clinical Trial Grant
Administered By
Ophthalmology, Vitreoretinal Diseases & Surgery
Awarded By
Regenxbio, Inc.
Start Date
October 4, 2021
End Date
September 30, 2026
Administered By
Ophthalmology, Vitreoretinal Diseases & Surgery
Awarded By
Regenxbio, Inc.
Start Date
October 4, 2021
End Date
September 30, 2026